Kenneth Gordon to Interleukin-23 Subunit p19
This is a "connection" page, showing publications Kenneth Gordon has written about Interleukin-23 Subunit p19.
Connection Strength
1.072
-
Risankizumab in moderate-to-severe plaque psoriasis. Immunotherapy. 2019 11; 11(16):1357-1370.
Score: 0.723
-
Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials. J Am Acad Dermatol. 2020 Apr; 82(4):936-945.
Score: 0.183
-
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018 08 25; 392(10148):650-661.
Score: 0.167